Pacritinib is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase 3 (FLT3) with IC50 of 23 and 22 nM, respectively, in cell-free tests. Phase 3.

 

Brand: BCM

 

Target: FLT; JAK; Tyrosine Kinases

 

Signaling Pathways: Angiogenesis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells; Tyrosine Kinase/Adaptors

 

Boiling Point: 711.4±70.0 °C at 760 mmHg

 

Flash Point: 384.0±35.7 °C

 

Vapour Pressure: 0.0±2.3 mmHg at 25°C

 

pKa: 9.56±0.20(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; insoluble in Ethanol.

 

GHS: GHS08, GHS09

 

Isomeric SMILES: C1CCN(C1)CCOC2=C3COC/C=C/COCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2  

 

InChIKey: HWXVIOGONBBTBY-ONEGZZNKSA-N  

 

InChI: InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+

 

Attribute
[Chem Name]	(16E)-11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(24),2(27),3,5,8(26),9,11,16,21(25),22-decaene
[Synonym]	Pacritinib; SB1518; SB-1518
[CAS No.]	937272-79-2
[MDL No.]	MFCD22572772
[Formula]	C28H32N4O3
[Molecular]	472.58
[Form]	Solid powder
[Storage]	Keep in dark place. Inert atmosphere, 2-8°C

Goods Tag